Literature DB >> 10980197

Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation.

D B Yap1, J K Hsieh, X Lu.   

Abstract

The ability of Mdm2 to inhibit the activities of a C-terminal truncated p53 mutant, p53-Delta30, which can bind Mdm2 but is resistant to Mdm2-mediated protein degradation was investigated. The inhibitory function of an Mdm2 mutant, Mdm2-Delta(222-437), which can bind p53 but is defective in targeting p53 for degradation was also studied. We have demonstrated that targeting p53 for degradation is the most effective way for Mdm2 to inhibit the apoptotic function of p53. However, we have also shown that Mdm2 can inhibit the transactivation function of p53 without targeting it for degradation, although Mdm2 releases the transrepression ability of p53 mainly by targeting it for degradation. The ability of Mdm2 to inhibit the apoptotic function of p53 was linked to its ability to inhibit the transrepression but not the transactivation function of p53. Furthermore, we have demonstrated that the transrepression function of p53 was specific to p53-induced apoptosis and was not simply a result of cell death.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980197     DOI: 10.1074/jbc.M004359200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.

Authors:  Stijn Heessen; Ainars Leonchiks; Natalia Issaeva; Anatoly Sharipo; Galina Selivanova; Maria G Masucci; Nico P Dantuma
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  A/T gap tolerance in the core sequence and flanking sequence requirements of non-canonical p53 response elements.

Authors:  Bi-He Cai; Chung-Faye Chao; Hwang-Chi Lin; Hua-Ying Huang; Reiji Kannagi; Jang-Yi Chen
Journal:  J Biochem       Date:  2016-01-27       Impact factor: 3.387

3.  Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation.

Authors:  Chiharu Uchida; Seiichi Miwa; Kyoko Kitagawa; Takayuki Hattori; Tomoyasu Isobe; Sunao Otani; Toshiaki Oda; Haruhiko Sugimura; Takehiko Kamijo; Keizou Ookawa; Hideyo Yasuda; Masatoshi Kitagawa
Journal:  EMBO J       Date:  2004-12-02       Impact factor: 11.598

4.  The p53-Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.

Authors:  N Nakashima; K Kuwano; T Maeyama; N Hagimoto; M Yoshimi; N Hamada; M Yamada; Y Nakanishi
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

5.  YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.

Authors:  Eva Grönroos; Alexei A Terentiev; Tanel Punga; Johan Ericsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-04       Impact factor: 11.205

6.  Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Authors:  Ranjan Chrisanthar; Stian Knappskog; Erik Løkkevik; Gun Anker; Bjørn Ostenstad; Steinar Lundgren; Terje Risberg; Ingvil Mjaaland; Gudbrand Skjønsberg; Turid Aas; Ellen Schlichting; Hans E Fjösne; Arne Nysted; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

Review 7.  Genetic Influences in Breast Cancer Drug Resistance.

Authors:  Adhitiya Daniyal; Ivana Santoso; Nadira Hasna Putri Gunawan; Melisa Intan Barliana; Rizky Abdulah
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-02-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.